|1.||Omura, S: 5 articles (07/2001 - 02/2000)|
|2.||Konieczny, Jolanta: 4 articles (04/2015 - 06/2011)|
|3.||Lenda, Tomasz: 4 articles (04/2015 - 06/2011)|
|4.||Le, Weidong: 4 articles (10/2010 - 12/2007)|
|5.||Qureshi, Nilofer: 4 articles (07/2010 - 08/2003)|
|6.||Czarnecka, Anna: 3 articles (04/2015 - 03/2014)|
|7.||Lorenc-Koci, Elżbieta: 3 articles (10/2014 - 06/2011)|
|8.||Jankovic, Joseph: 3 articles (01/2012 - 12/2007)|
|9.||Pasquini, J M: 3 articles (06/2009 - 05/2000)|
|10.||Vogel, Stefanie N: 3 articles (10/2008 - 08/2003)|
07/01/2003 - "Lactacystin was also effective in inducing apoptosis in lymphoma cells from MCL patients. "
07/01/2003 - "The present study investigated the effect of a specific proteasome inhibitor, lactacystin, on cell cycle progression and apoptosis in two lymphoma cell lines harbouring the t(11;14)(q13;q32) and additional cytogenetic alterations, including p53 mutation (NCEB) and p16 deletion (Granta 519). "
05/01/2007 - "Smac-mediated sensitization of human B-lymphoma cells to staurosporine- and lactacystin-triggered apoptosis is apoptosome-dependent."
07/01/2000 - "Employing as a model system castanospermine-treated BW5147 mouse T-lymphoma cells in which accelerated degradation of the T-cell receptor (TCR) alpha subunit takes place (Kearse et al. (1994) EMBO J., 13, 3678-3686), we noted that both lactacystin and N-acetyl-L-leucyl-L-leucyl-L-norleucinal, but not leupeptin, brought about a rapid and substantial reduction in the release of free polymannose oligosaccharides into the cytosol during pulse-chase studies, while the oligosaccharides in the intravesicular compartment remained unchanged, as measured by streptolysin O permeabilization. "
02/01/2013 - "Rat C6 glioma cells were cultured with or without lactacystin. "
05/01/2006 - "We tested the efficacy of lactacystin incorporated into controlled-release polymers for treating experimental gliomas. "
02/01/2013 - "The proteasome inhibitor lactacystin exerts its therapeutic effects on glioma via apoptosis: an in vitro and in vivo study."
02/01/2013 - "To examine the effect and underlying mechanism of action of the proteasome inhibitor lactacystin on glioma, in vitro and in vivo. "
05/01/2006 - "Lactacystin, a proteasome-inhibitor, has been shown to induce apoptosis of experimental gliomas in vitro. "
07/01/2001 - "Since cathepsin A is also a tumor-associated enzyme, further research is needed to clarify its role and the significance of its inhibition by lactacystin in tumor biology."
10/14/1996 - "We found that the proteasome-specific inhibitor lactacystin (LC) induced expression of the cell cycle inhibitor p21WAF1/CIP1 in human cancer cells regardless of their p53 status. "
05/01/2000 - "These results indicate that lactacystin could serve as a new therapeutic agent to circumvent resistance to topo II-targeted chemotherapy in solid tumors."
05/01/2006 - "Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers."
05/01/2006 - "The efficacy of 1, 1.3, 1.5 and 1.7% lactacystin/pCPP : SA polymers was determined in Fischer-344 rats intracranially challenged with 9L and treated either simultaneously or 5 days after tumor implantation. "
08/02/2002 - "Proteasome inhibition with either carbobenzoxy-leucyl-leucyl-phenylalaninal or lactacystin led to a loss of dually phosphorylated, activated p44/42 MAPK in A1N4-myc human mammary and MDA-MB-231 breast carcinoma cells in a dose- and time-dependent fashion. "
01/01/2001 - "We report in this work that lactacystin, at concentrations that do not appear harmful, increased cisplatin toxicity in three resistant human ovarian carcinoma cell lines. "
09/01/1999 - "In addition to the angiogenesis inhibitor TNP-470, lactacystin also inhibited the growth of HUVECs selectively at about a 20 times lower concentration than that of other human cell lines, including normal fibroblasts and carcinoma cells. "
01/01/2003 - "Here it is shown that treatment of A431 carcinoma cells with proteasome inhibitors Mg132 and lactacystin results in increasing the PLC gamma 1 intracellular level. "
08/05/2004 - "The proteasome inhibitors, epoxomicin, lactacystin and carbobenzoxy-leucyl-leucyl-leucinal, stimulate the release of arachidonic acid from rat glial, human colon carcinoma, human breast carcinoma and the rat liver cells. "
|5.||Melanoma (Melanoma, Malignant)
07/01/2001 - "Exposure of three murine melanoma cell lines with different metastatic potential to lactacystin at a concentration of 5 microM for 6 h caused a significant reduction in the carboxypeptidase activity of this enzyme, while the inhibitory activity remained unchanged for at least 12 h. "
03/15/1999 - "Furthermore, treatment of melanoma cells expressing the MAGE-3 protein with lactacystin resulted in efficient lysis by MAGE-3271-279-specific CTL. "
07/01/2001 - "In vitro lactacystin metabolite, beta-lactone, at a concentration of 1 microM, significantly suppressed cathepsin A activity in B78 melanoma cell lysates by about 50%. "
07/01/2001 - "Lactacystin inhibits cathepsin A activity in melanoma cell lines."
06/15/1999 - "Presentation of the C-terminal ILKEPVHGV epitope is impaired in ME275 melanoma cells by treatment with lactacystin, and is independent of expression of the IFN-gamma-inducible proteasome beta subunits LMP2 and LMP7. "
|1.||Proteasome Endopeptidase Complex (Proteasome)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||3- (4- methylphenylsulfonyl)- 2- propenenitrile
|8.||decanedioic acid- 4,4'- (1,3- propanediylbis(oxy))bis(benzoic acid) copolymer (Gliadel)
|9.||NF-kappa B (NF-kB)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)